gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate-649): a randomised, open-label, phase 3 trial[J]. Lancet. 2021 Jul 3;398(10294):27-40.
[2] Yelena Y Janjigian, Kohei Shitara, Markus Moehler ,et al.First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate-649): a randomised, open-label, phase 3 trial[J]. Lancet. 2021 Jul 3;398(10...
吴晓滨教授:随着CheckMate-649研究公布4年长期随访生存数据,进一步延长患者生存已不再是梦想,纳武利尤单抗联合化疗可使部分患者达到长期生存,这在整个胃癌治疗领域较为罕见。吴一龙教授曾说:“肺癌可以作为一个慢性疾病长期维持治疗”,如今胃癌...
[3].Janjigian Y Y, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial[J]. The Lancet, 2021, 398(10294): 27-...
2010年,ToGA研究在《柳叶刀》(Lancet)杂志正式发表,俨然平地一声惊雷,意味着HER2阳性的晚期胃癌正式有了靶向药物可以用于延长患者生存,由此开启了胃癌靶向治疗的新时代。难能可贵的是,在东西方围手术期治疗方案难以趋同的时候,这个靶向治疗的结论却几乎毫无异议。
3. Janjigian, YY et. al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastroesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. The Lancet, VOLUME 402, ISSUE 10418, P2197-2208. ...
参考文献: 1. Yelena Y Janjigian, Kohei Shitara, Markus Moehler ,et al.First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial[J]. Lancet. 2021 Jul ...
2. Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair deficient/microsatellite instability-high colorectal cancer (CheckMate 142): results of an open-label, multicenter, phase 2 study. Lancet Oncology, 2017,18(9):1182–1191. ...
The diagnosis of brain metastasis (BrM) has historically been a dooming diagnosis that is nothing less than a death sentence, with few treatment options for palliation or prolonging life. Among the few treatment options available, brain radiotherapy (RT)
2. Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair deficient/microsatellite instability-high colorectal cancer (CheckMate 142): results of an open-label, multicenter, phase 2 study. Lancet Oncology, 2017,18(9):1182–1191. ...